Healthcare

Starpharma (ASX:SPL) has launched a $32 millionCapitalraising to support the progression of its lead oncology candidate DEP HER2-Lu into first-in-human clinical testing.

Telix Pharmaceuticals (ASX:TLX) has reported its strongest quarterly revenue performance to date and reaffirmed that combined 2026 revenue and other income is expected to exceed US$1 billion.

LTR Pharma (ASX:LTP) has received ethics approval to begin human testing of OROFLOW, its second intranasal drug candidate targeting oesophageal motility disorders.

Mesoblast (ASX:MSB) has completed the first full year of commercial sales for RYONCIL, reporting US$115 million in net revenue since the cell therapy received U.S. approval.

Neuren Pharmaceuticals (ASX:NEU) has reported its strongest quarter yet from DAYBUE, the Rett syndrome treatment licensed to U.S. partner Acadia Pharmaceuticals, leading to another upgrade in the company's expected 2026 royalty income.

Neurotech International Limited (ASX:NTI) has reached a regulatory milestone for its NTI164Drug Developmentprogram after the U.S.Food and Drug Administration (FDA)cleared the company’s Investigational New Drug (IND) application.

Nyrada Inc. (ASX:NYR) has reached a key clinical development milestone after dosing the first patient in its Phase IIa PROTECT-MI trial, moving its lead drug candidate Xolatryp into human testing for heart attack patients.